Neuralstem Inc. (CUR)

1.63
AMEX : Health Technology
Prev Close 1.63
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.88 / 6.60
Avg Volume 193.80K
Exchange AMEX
Shares Outstanding 15.15M
Market Cap 25.14M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.

Neuralstem Reports Last Subject Out In Phase 2 Trial Of NSI-189 For Major Depressive Disorder

Top Line Results Expected in 3Q 2017

Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical And Business Update

Phase 2 MDD clinical trial results expected in 3Q17, Extended runway of cash into 3Q18

Neuralstem Expands Phase 1 Safety Trial Of NSI-566 Neural Stem Cells In Spinal Injury

Investigating New Patient Cohort with Cervical Injury

TheStreet Quant Rating: E+ (Sell)